LSD-induced Hallucinogen Persisting Perception Disorder with depressive features treated with reboxetine: case report.
We would like to present the case of a patient who had a prior history of cannabis, ecstasy (MDMA) and LSD abuse and who developed both Hallucinogen Persisting Perception Disorder (HPPD) and a major depressive episode. Following two unsuccessful SSRIs trials, reboxetine was prescribed. During a six-month follow-up period on reboxetine 6 mg./day, no exacerbation of the visual disturbance or recurrence of the depressive features were reported. Reboxetine may have an alpha 2 adrenoreceptor modulating effect on both noradrenaline and serotonin release, thus reboxetine's alpha 2 adrenoreceptor modulating effect on noradrenaline release may affect sympathetic activity and be involved in the recovery process.
Lerner
Arturo G
AG
Lev Hasharon Mental Health Medical Center, Pardessya, POB 90000, Netanya, 42100, Israel. lerneram@internet-zahav.net
Shufman
Emi
E
Kodesh
Arad
A
Kretzmer
Gavin
G
Sigal
Mircea
M
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000328:Adult; D003863:Depression / Q000209:etiology*; D006212:Hallucinations / Q000139:chemically induced / Q000188:drug therapy / Q000523:psychology; D006213:Hallucinogens / Q000009:adverse effects*; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000009:adverse effects*; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D000077593:Reboxetine; D012720:Severity of Illness Index
D018759:Adrenergic Uptake Inhibitors; D006213:Hallucinogens; D009025:Morpholines; D008238:Lysergic Acid Diethylamide; D000077593:Reboxetine